FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2085667526> ?p ?o ?g. }

• W2085667526 endingPage "2525" @default.
• W2085667526 startingPage "2525" @default.
• W2085667526 abstract "Rheumatoid arthritis (RA) and psoriasis have been linked with insulin resistance and diabetes mellitus (DM). Prior investigations suggest that systemic immunosuppressive drugs may improve insulin resistance and reduce the risk of DM.To compare the risk of newly recorded DM among participants diagnosed with RA or psoriasis based on use of a variety of disease-modifying antirheumatic drugs (DMARDs).A retrospective cohort study among 121,280 patients with a diagnosis of either RA or psoriasis on at least 2 visits. The analyses were conducted in the context of 2 large health insurance programs, 1 in Canada and 1 in the United States, using administrative data. The mean follow-up was 5.8 months and began with the first prescription for a DMARD after study eligibility was met. Drug regimens were categorized into 4 mutually exclusive groups: (1) tumor necrosis factor (TNF) inhibitors with or without other DMARDs; (2) methotrexate without TNF inhibitors or hydroxychloroquine; (3) hydroxychloroquine without TNF inhibitors or methotrexate; or (4) other nonbiologic DMARDs without TNF inhibitors, methotrexate, or hydroxychloroquine (reference exposure).Newly recorded DM as evidenced by a new diagnosis of DM with use of a DM-specific medication.The study cohort consisted of 13,905 participants with 22,493 treatment episodes starting 1 of the categories of DMARD regimens between January 1996 and June 2008. New diabetes cases and respective incidence rates per 1000 person-years were: other nonbiologic DMARDs (55 cases among 3993 treatment episodes; rate, 50.2; 95% confidence interval [CI], 47.3-53.2); TNF inhibitors (80 cases among 4623 treatment episodes; rate, 19.7; 95% CI, 19.1-20.3); methotrexate (82 cases among 8195 treatment episodes; rate, 23.8; 95% CI, 23.0-24.6); and hydroxychloroquine (50 cases among 5682 treatment episodes; rate, 22.2; 95% CI, 21.3-23.1). The multivariate adjusted hazard ratios for DM were 0.62 (95% CI, 0.42-0.91) for TNF inhibitors, 0.77 (95% CI, 0.53-1.13) for methotrexate, and 0.54 (95% CI, 0.36-0.80) for hydroxychloroquine compared with other nonbiologic DMARDS.Among patients with RA or psoriasis, the adjusted risk of DM was lower for individuals starting a TNF inhibitor or hydroxychloroquine compared with initiation of other nonbiologic DMARDs." @default.
• W2085667526 created "2016-06-24" @default.
• W2085667526 creator A5050398307 @default.
• W2085667526 date "2011-06-22" @default.
• W2085667526 modified "2023-10-04" @default.
• W2085667526 title "Association Between Disease-Modifying Antirheumatic Drugs and Diabetes Risk in Patients With Rheumatoid Arthritis and Psoriasis" @default.
• W2085667526 cites W1581371422 @default.
• W2085667526 cites W176067967 @default.
• W2085667526 cites W1775492403 @default.
• W2085667526 cites W1964472208 @default.
• W2085667526 cites W1977476168 @default.
• W2085667526 cites W1982112254 @default.
• W2085667526 cites W1990795149 @default.
• W2085667526 cites W1995468535 @default.
• W2085667526 cites W2001727746 @default.
• W2085667526 cites W2010378610 @default.
• W2085667526 cites W2011966376 @default.
• W2085667526 cites W2012487908 @default.
• W2085667526 cites W2016418114 @default.
• W2085667526 cites W2018135697 @default.
• W2085667526 cites W2022665587 @default.
• W2085667526 cites W2024378513 @default.
• W2085667526 cites W2034948055 @default.
• W2085667526 cites W2035292279 @default.
• W2085667526 cites W2037882607 @default.
• W2085667526 cites W2047210903 @default.
• W2085667526 cites W2053237747 @default.
• W2085667526 cites W2056329160 @default.
• W2085667526 cites W2057014857 @default.
• W2085667526 cites W2064119981 @default.
• W2085667526 cites W2072781226 @default.
• W2085667526 cites W2129168200 @default.
• W2085667526 cites W2137499656 @default.
• W2085667526 cites W2139203772 @default.
• W2085667526 cites W2147612813 @default.
• W2085667526 cites W2159087408 @default.
• W2085667526 cites W2164595809 @default.
• W2085667526 cites W2165401890 @default.
• W2085667526 cites W2170973130 @default.
• W2085667526 cites W2171165571 @default.
• W2085667526 cites W2184850276 @default.
• W2085667526 cites W65358577 @default.
• W2085667526 cites W1996842470 @default.
• W2085667526 doi "https://doi.org/10.1001/jama.2011.878" @default.
• W2085667526 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21693740" @default.
• W2085667526 hasPublicationYear "2011" @default.
• W2085667526 type Work @default.
• W2085667526 sameAs 2085667526 @default.
• W2085667526 citedByCount "330" @default.
• W2085667526 countsByYear W20856675262012 @default.
• W2085667526 countsByYear W20856675262013 @default.
• W2085667526 countsByYear W20856675262014 @default.
• W2085667526 countsByYear W20856675262015 @default.
• W2085667526 countsByYear W20856675262016 @default.
• W2085667526 countsByYear W20856675262017 @default.
• W2085667526 countsByYear W20856675262018 @default.
• W2085667526 countsByYear W20856675262019 @default.
• W2085667526 countsByYear W20856675262020 @default.
• W2085667526 countsByYear W20856675262021 @default.
• W2085667526 countsByYear W20856675262022 @default.
• W2085667526 countsByYear W20856675262023 @default.
• W2085667526 crossrefType "journal-article" @default.
• W2085667526 hasAuthorship W2085667526A5050398307 @default.
• W2085667526 hasBestOaLocation W20856675261 @default.
• W2085667526 hasConcept C126322002 @default.
• W2085667526 hasConcept C134018914 @default.
• W2085667526 hasConcept C151730666 @default.
• W2085667526 hasConcept C16005928 @default.
• W2085667526 hasConcept C2777077863 @default.
• W2085667526 hasConcept C2777226972 @default.
• W2085667526 hasConcept C2777575956 @default.
• W2085667526 hasConcept C2779123688 @default.
• W2085667526 hasConcept C2779134260 @default.
• W2085667526 hasConcept C2779343474 @default.
• W2085667526 hasConcept C2779722408 @default.
• W2085667526 hasConcept C2780564577 @default.
• W2085667526 hasConcept C2781059491 @default.
• W2085667526 hasConcept C3008058167 @default.
• W2085667526 hasConcept C524204448 @default.
• W2085667526 hasConcept C555293320 @default.
• W2085667526 hasConcept C71924100 @default.
• W2085667526 hasConcept C72563966 @default.
• W2085667526 hasConcept C86803240 @default.
• W2085667526 hasConceptScore W2085667526C126322002 @default.
• W2085667526 hasConceptScore W2085667526C134018914 @default.
• W2085667526 hasConceptScore W2085667526C151730666 @default.
• W2085667526 hasConceptScore W2085667526C16005928 @default.
• W2085667526 hasConceptScore W2085667526C2777077863 @default.
• W2085667526 hasConceptScore W2085667526C2777226972 @default.
• W2085667526 hasConceptScore W2085667526C2777575956 @default.
• W2085667526 hasConceptScore W2085667526C2779123688 @default.
• W2085667526 hasConceptScore W2085667526C2779134260 @default.
• W2085667526 hasConceptScore W2085667526C2779343474 @default.
• W2085667526 hasConceptScore W2085667526C2779722408 @default.
• W2085667526 hasConceptScore W2085667526C2780564577 @default.
• W2085667526 hasConceptScore W2085667526C2781059491 @default.
• W2085667526 hasConceptScore W2085667526C3008058167 @default.
• W2085667526 hasConceptScore W2085667526C524204448 @default.

• next